We aimed to write a review by referring to recent studies about Gal-3 in the etiopathogenesis of CAD, its prognostic significance, and its contribution to the treatment regimen.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Inflammation is one of the cornerstones of atherosclerosis.
📊
Temel Bulgular & Veri:Galectin-3 (Gal-3) acts on the stages of the inflammatory process.
💡
Sonuç & Katkı:We aimed to write a review by referring to recent studies about Gal-3 in the etiopathogenesis of CAD, its prognostic significance, and its contribution to the treatment regimen.
Inflammation is one of the cornerstones of atherosclerosis. Galectin-3 (Gal-3) acts on the stages of the inflammatory process. Gal-3 is a candidate for being a valuable marker for heart failure (HF) and coronary artery disease (CAD). Further studies are needed for the diagnosis and follow-up of CAD. In the literature, the relationship between Gal-3 and CAD has not been researched sufficiently. We aimed to write a review by referring to recent studies about Gal-3 in the etiopathogenesis of CAD, its prognostic significance, and its contribution to the treatment regimen.
AŞKIN, L., AŞKIN, H., TANRIVERDİ, O., ÖZYILDIZ, A. G., HİDAYET, Ş. (2021). An overview about galectin-3 and its relationship with cardiovascular diseases. Journal of Surgery and Medicine, Cilt: 5 - Sayı: 12, 1218–1220. https://ajindex.com/articles/779786
Askin L, Tanrıverdi O. An Overview of Clinical Studies on Endocan and Cardiovascular Disease. Erciyes Med J. 2021;43(3):233-6. doi: 10.14744/etd.2020.09699
Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020;21(23):9232. doi: 10.3390/ijms21239232
Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2015;35(3):725-32. doi: 10.1161/ATVBAHA.114.304964
Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121-8. doi: 10.1161/01.CIR.0000147181.65298.4D
Kusaka H, Yamamoto E, Hirata Y, Fujisue K, Tokitsu T, Sugamura K, et al. Clinical significance of plasma galectin-3 in patients with coronary artery disease. Int J Cardiol. 2015;201:532-4. doi: 10.1016/j.ijcard.2015.08.099
Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol. 2015;182:168-70. doi: 10.1016/j.ijcard.2014.12.137
Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Küpper I, et al. Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol. 2007;171(2):463-72. doi: 10.2353/ajpath.2007.060906
Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107-17. doi: 10.1161/CIRCHEARTFAILURE.112.971168
Lepojärvi ES, Piira OP, Pääkkö E, Lammentausta E, Risteli J, Miettinen JA, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015;6:200. doi: 10.3389/fphys.2015.00200
McCullough PA. Practical experience using galectin-3 in heart failure. Clin Chem Lab Med. 2014;52(10):1425-31. doi: 10.1515/cclm-2014-0278
Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, et al. Elevated plasma galectin-3 is associated with near-term